Neurobiological Predictors of Huntington's Disease (PREDICT-HD)

Neurobiological Predictors of Huntington's Disease (PREDICT-HD)

« return to clinical trials
HUNTINGTON'S DISEASE CLINIC

PREDICT-HD is an observational study for healthy at-risk individuals conducted in collaboration with the Huntington Study Group, University of Rochester, New York, USA.

Overview

The purpose of this study is to prepare for a trial of experimental drugs aimed at slowing or postponing the onset of HD. It aims to address questions about: (1) the earliest changes in the brain, intellect and behavior; (2) neurobiological factors that influence the age of onset; and (3) the most accurate tests that clinicians can use in detecting HD onset. The study is ongoing and enrolment is open.

Design

  • 625 participants needed (both gene-positives and gene-negatives) in Canada, the US, and Australia.

  • Clinical evaluations every 12 months for 36 months (total of 4 visits) including:

    • Neurological examination;

    • Psychological and behavioral assessments;

    • Brain imaging (MRI scan) at baseline and 24 months;

    • Bideotaping and audiotaping during all visits; and

    • Blood samples.

Eligibility Criteria

In order to participate in this trial, the patient must:

  • Be 26 years of age or older;

  • Have been tested for the HD gene;

  • Exhibit no signs or symptoms of HD; and

  • Have a support person accompanying to the visits.

Enrollment has started in September 2002 and is ongoing.

Site Investigation Team

  • Dr. Lynn Raymond (site investigator)

  • Joji Decolongon (site co-ordinator)

If interested, please call +1 (604) 822-7928 for further information or contact Joji Decolongon via e-mail at joji@cmmt.ubc.ca.